Ars Pharmaceuticals (SPRY) | Stock Overview & Key Data
Ars Pharmaceuticals Performance Comparison
Stock Range
Today's Range
Low: $13.45
High: $14.97
on August 22, 2025
52 Week Range
Low: $10.00
High: $18.90
on March 4, 2025
on June 27, 2025
All-Time High: $63.41 on March 15, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.4B
EPS
-0.48
P/E Ratio (TTM)
168.25
Forward P/E
-18.14
P/B Ratio
7.08
PEG Ratio
0.66
Div. Yield
N/A
ROE
-23.56%
Beta
0.962
Debt to Equity
38.28
Financial Highlights
Profitability
Gross Margin
68.29%
Operating Margin
-302.95%
Profit Margin
-42.74%
Returns and Earnings
Return on Assets (TTM)
-13.85%
Return on Equity (TTM)
-23.56%
EBITDA
$-58.7M
Net Income (TTM)
$-48.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$1.15
Quarterly Revenue Growth (YoY)
3,043.40%
Quarterly Earnings Growth (YoY)
3,043.40%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Ars Pharmaceuticals SPRY | 1.36B Small-cap | -7.02% | -23.19% | -6.96% | 24.75% | 26.14% | 4.17% | 157.63% | -46.00% |
| Vertex VRTX | 100.19B Large-cap | 0.62% | -15.94% | -8.94% | -17.95% | -2.60% | -17.90% | 40.27% | 46.36% |
| Regeneron REGN | 62.88B Large-cap | 1.56% | 5.09% | -1.23% | -17.35% | -17.58% | -50.84% | -1.12% | -2.18% |
| Cg Oncology CGON | 1.99B Small-cap | 4.75% | 3.50% | 4.50% | 0.52% | -7.08% | -27.31% | -23.18% | -23.18% |
| Adaptive ADPT | 1.92B Small-cap | -0.31% | 23.46% | 47.06% | 54.39% | 110.02% | 167.70% | 24.14% | -68.12% |
| Vericel VCEL | 1.80B Small-cap | 2.07% | -2.50% | -10.51% | -29.24% | -32.81% | -24.87% | 36.79% | 126.21% |
Ownership & Short Interest
Insider Ownership
16.83%
Institutional Ownership
85.92%
Shares Short
15M
Short Ratio
11.21
Short % of Shares Outstanding
25.55%
Average 10-Day Volume
2M
Average 90-Day Volume
2M
Ars Pharmaceuticals Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Ars Pharmaceuticals would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SPRY's 52-week high and low?
- In the last 52 weeks, Ars Pharmaceuticals reached a high of $18.90 (on June 27, 2025) and a low of $10.00 (on March 4, 2025).
- What is the market cap and P/E ratio for SPRY?
- Curious about Ars Pharmaceuticals's size and valuation? Its market capitalization stands at 1.36B. When it comes to valuation, the P/E ratio (trailing twelve months) is 168.25, and the forward P/E (looking ahead) is -18.14.
- Does SPRY pay dividends? If so, what's the yield?
- As for dividends, Ars Pharmaceuticals isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Ars Pharmaceuticals's main competitors or similar companies to consider before investing?
When looking at Ars Pharmaceuticals, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.19B Healthcare Biotechnology -17.90% 40.27% Regeneron
REGN62.88B Healthcare Biotechnology -50.84% -1.12% Cg Oncology
CGON1.99B Healthcare Biotechnology -27.31% -23.18% Adaptive
ADPT1.92B Healthcare Biotechnology 167.70% 24.14% Vericel
VCEL1.80B Healthcare Biotechnology -24.87% 36.79% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ars Pharmaceuticals Inc? (e.g., ROE, Debt/Equity)
- To get a sense of Ars Pharmaceuticals's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -23.56%, the Debt to Equity ratio from the most recent quarter is 38.28, and its Gross Profit Margin stands at 68.29%.
- What is the recent revenue and earnings growth for SPRY?
- Looking at Ars Pharmaceuticals's growth, its revenue over the trailing twelve months (TTM) was $112M. Compared to the same quarter last year (YoY), quarterly revenue grew by 3,043.40%, and quarterly earnings saw a YoY growth of 3,043.40%.
- How much of SPRY stock is held by insiders and institutions?
- Wondering who owns Ars Pharmaceuticals stock? Company insiders (like executives and directors) hold about 16.83% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 85.92%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.